from February 2013 seropositive patients will undergo tests of an AIDS vaccine developed in France, to investigate its effectiveness in humans, announced the public agency of hospitals of Marseilles.
after passing through multiple clinical trials, France health agencies adopted the opinion and will start with the e xperimentacion in humans who have the human immunodeficiency virus (HIV).
with this vaccine is expected to replace the current treatment that patients undergo with HIV called therapy Triple. responsible for the vaccine, Erwann Loret scientist explained that making available treatment Triple for the 33 million HIV infected people is impossible, vaccination is the only therapeutic treatment appropriate AIDS , said Loret, director of the laboratory of biology EstructurMarseille’s La Timone.
focalization of the Tat protein is the key element for the efficacy of this vaccine against AIDS, since the protein is what gives subsistence to the virus in cells, says Dr. Loret our vaccine will deal directly with the shield of the infected cells .
vaccine aims to weaken the Tat protein, produce antibodies in the immune system and thus eliminate cells infected by the Virus of immunodeficiency human.
the results will be announced until 2015, when it can be demonstrated the efficacy of the vaccine in humans, hitherto research in vitro e in vivo to been excellent, and positive results in experiments with monkeys have been more than favorable, and hope to counter the HIV virus in human body.
